Clinical Trial

Combined Locoregional Treatment With Immunotherapy for Unresectable HCC.

Unknown Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated August 1, 2024 (before its estimated October 30, 2024 completion). Its status may not reflect the trial's current state.
Summary
Efficacy and Safety of Locoregional treatments Combined With PD-1 Inhibitor in Patients With Unresectable Hepatocellular Carcinoma.
Protocol Amendment History 1 change
critical Trial status changed: Active, Not Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT04220944
Lead Sponsor Shanghai Zhongshan Hospital
Collaborators: Innovent Biologics (Suzhou) Co. Ltd.
Conditions Hepatic Carcinoma
Enrollment 45 participants
Start Date 2020-01-01
Primary Completion 2024-10-30 (estimated)
Study Completion 2024-12-30 (estimated)
Updated on ClinicalTrials.gov 2024-08-01